References
Natalizumab for the treatment of highly active MS: risks and benefits

Abstract
This article discusses the history of natalizumab (Tysabri), the first monoclonal antibody used to treat multiple sclerosis. It reviews how the drug's difficult beginnings and controversial past has changed the treatment is monitored treatment. The article looks at the role of clinicians in maintaining patient safety, the benefits and risk profile of this treatment, and ways of optimising practice to provide gold standard nationalised natalizumab services throughout the UK.
Multiple sclerosis (MS) is the most common neurological disease in young adults, affecting about 100 000 people in the UK (MS Trust, 2018). MS is an autoimmune disease of the central nervous system (CNS), which causes demylenation. Its symptoms result from inflammatory injury and neurodegeneration. In MS, autoreactive lymphocytes cross the blood brain barrier (BBB) and enter the CNS, causing inflammation, neuronal demyelination, axonal damage, and neurological degeneration and dysfunction (Bradstander and Katz Sand, 2017).
MS is classified into three main types: relapsing remitting multiple sclerosis (RRMS), secondary progressive multiple sclerosis (SPMS) and primary progressive multiple sclerosis (PPMS). RRMS affects 85% of the MS population (MS Trust, 2018). It is categorised by episodes of new or worsening symptoms that last for more than 48 hours (relapse) followed by periods of recovery and remission (remission). This type of MS is more prevalent in 20–30-year-old women. There are a number of disease modifying therapies (DMTs) that aim to reduce the impact of relapses and the accumulation of disability. Each of these treatments has different mode of action, efficacy, route of administration and licencing criteria. The medication chosen for someone with MS will be a decision for the patient and their neurologist to make together by looking at the patient's disease activity, lifestyle and life choices (ie starting a family) (NHS England, 2018).
Register now to continue reading
Thank you for visiting Journal of Prescribing Practice and reading some of our peer-reviewed resources for prescribing professionals. To read more, please register today. You’ll enjoy the following great benefits:
What's included
-
Limited access to our clinical or professional articles
-
New content and clinical newsletter updates each month